A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Trial Details

NCT ID
NCT07361497
Phase
PHASE3
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pumitamig
  • Durvalumab
Locations (sample)
  • Daphne, Alabama, United States|30.60353,-87.9036
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Golden, Colorado, United States|39.75554,-105.2211
  • Newark, Delaware, United States|39.68372,-75.74966
  • Ocala, Florida, United States|29.1872,-82.14009

Key Eligibility Criteria

  • Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III dis…
  • Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy).
  • Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →